Induction of human leukocyte antigen (HLA)-A2-restricted and MAGE-3- gene-derived peptide-specific cytolytic T lymphocytes using cultured dendritic cells from an HLA-A2 esophageal cancer patient

Journal of Surgical Oncology

Volumn 71, Issue 1, 1999, Pages 16-21

  Kanaoka, Shunji ^a   Yamasaki, Seiji ^a   Okino, Takashi ^a   Inoue, Naoya ^a   Shimada, Yutaka ^a   Kaneko, Midori ^a   Otaka, Akira ^a   Fujii, Nobutaka ^a   Imamura, Masayuki ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Antigen presenting cell; Antigenic peptide; Antitumor immunity; Vaccine therapy

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A2 ANTIGEN; INTERLEUKIN 4; PEPTIDE; TUMOR NECROSIS FACTOR;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CANCER CELL DESTRUCTION; CANCER IMMUNIZATION; CANCER IMMUNOLOGY; CARCINOMA CELL; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ESOPHAGUS CANCER; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; DENDRITIC CELLS; ESOPHAGEAL NEOPLASMS; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY, ACTIVE; NEOPLASM PROTEINS; PEPTIDES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

EID: 0032984378     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(199905)71:1<16::AID-JSO4>3.0.CO;2-A     Document Type: Article

References (22)

1. Boon T, van der Bruggen P: Human tumor antigens recognized by T lymphocytes. J Exp Med 1996;183:725-729.
2. Celis E, Tsai V, Crimi C, et al.: Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 1994;91:2105-2109.
3. Marchand M, Weynants P, Rankin E, et al.: Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 1995;63:883-885.
4. Yamasaki S, Okino T, Chakraborty NG, et al.: Presentation of synthetic peptide antigen encoded by the MAGE-1 gene by granulocyte/macrophage-colony-stimulating-factor-cultured macrophages from HLA-A1 melanoma patients. Cancer Immunol Immunother 1995;40:268-271.
5. Sallusto F, Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994;179:1109-1118.
6. Romani N, Gruner S, Brang D, et al.: Proliferating dendritic cell progenitors in human blood. J Exp Med 1994;180:83-93.
7. van der Bruggen P, Bastin J, Gajewski T, et al.: A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 1994;24:3038-3043.
8. Shimada Y, Imamura M, Wagata T, et al.: Characterization of 21 newly established esophageal cancer cell lines. Cancer 1992;69: 277-284.
9. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
10. Yajima H, Fujii N, Funakoshi S, et al.: New strategy for the chemical synthesis of proteins. Tetrahedron 1988;44:805-819.
11. Espevik T, Nissen-Meyer J: A highly sensitive cell line, WEHI164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods 1986;95:99-105.
12. Traversari C, van der Bruggen P, Luescher IF, et al.: A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992;176:1453-1457.
13. Salgaller ML, Weber JS, Koenig S, et al.: Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide. Cancer Immunol Immunother 1994:39:105-116.
14. Valmori D, Lienard D, Waanders G, et al.: Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients. Cancer Res 1997;57:735-741.
15. Dong RP, Kimura A, Okubo R, et al.: HLA-A and DPB1 loci confer susceptibility to Graves' disease. Hum Immunol 1992;35: 165-172.
16. Toh Y, Yamana H, Shichijo S, et al.: Expression of MAGE-1 gene by esophageal carcinomas. Jpn J Cancer Res 1995;86:714-717.
17. Inoue H, Mori M, Honda M, et al.: The expression of tumor-rejection antigen "MAGE" genes in human gastric carcinoma. Gastroenterology 1995;109:1522-1525.
18. Liu T, Chambers B, Diehl AD, et al.: TAP peptide transporter-independent presentation of heat-killed Sendai virus antigen on MHC class I molecules by splenic antigen-presenting cells. J Immunol 1997;159:5364-5371.
19. Zitvogel L, Mayordomo JI, Tjandrawan T, et al.: Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996;183:87-97.
20. Mukherji B, Chakraborty NG, Yamasaki S, et al.: Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA 1995;92:8078-8082.
21. Hu X, Chakraborty NG, Sporn JR, et al.: Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 1996;56:2479-2483.
22. Hsu FJ, Benike C, Fagnoni F, et al.: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-58.